

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2023 Defense Health Agency **Date:** April 2022

Appropriation/Budget Activity 0130: <i>Defense Health Program I BA 2: RDT&E</i>	R-1 Program Element (Number/Name) PE 0605145DHA I <i>Medical Products and Support Systems Development</i>
---	---

COST (\$ in Millions)	Prior Years	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total	FY 2024	FY 2025	FY 2026	FY 2027	Cost To Complete	Total Cost
Total Program Element	72.921	21.068	21.489	64.030	0.000	64.030	58.562	57.895	62.193	63.048	Continuing	Continuing
500A: <i>CSI - Congressional Special Interests</i>	18.382	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing
375: <i>GDF - Medical Products and Support System Development</i>	54.539	21.068	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing
375A: <i>GDF - Medical Simulation and Training</i>	0.000	0.000	2.000	2.000	0.000	2.000	2.000	2.000	2.000	2.040	Continuing	Continuing
375B: <i>GDF - Medical Readiness</i>	0.000	0.000	8.536	5.725	0.000	5.725	5.674	5.967	7.490	7.641	Continuing	Continuing
375C: <i>GDF - Medical Combat Support</i>	0.000	0.000	10.953	14.194	0.000	14.194	14.683	14.838	13.770	14.045	Continuing	Continuing
375D: <i>GDF - Medical Products and Support System Development</i>	0.000	0.000	0.000	42.111	0.000	42.111	36.205	35.090	38.933	39.322	Continuing	Continuing

A. Mission Description and Budget Item Justification

Guidance for Development of the Force – Medical Products and Support Systems Development: This program element (PE) provides funding for system development and demonstration of medical commodities delivered from the various medical advanced development and prototyping Department of Defense (DoD) Components that are directed at meeting validated requirements prior to full-rate initial production and fielding, including initial operational test and evaluation and clinical trials for products that require US Food and Drug Administration approval.

Development, test, and evaluation in this PE is designed to address requirements identified through the Joint Capabilities Integration and Development System and other Department of Defense operational needs. Medical development, test, and evaluation priorities for the Defense Health Program (DHP) are guided by, and will support, the National Defense Strategy, the Joint Staff Surgeon’s Joint Concept for Health Services, and other overarching DoD strategic framework documents.

Coordination occurs through the planning and execution activities of the Defense Health Agency Component Acquisition Executive (DHA CAE) as the Milestone Decision Authority for medical materiel development efforts. As technologies mature, the most promising efforts will transition to production and deployment.

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2023 Defense Health Agency **Date:** April 2022

Appropriation/Budget Activity 0130: <i>Defense Health Program I BA 2: RDT&E</i>	R-1 Program Element (Number/Name) PE 0605145DHA I <i>Medical Products and Support Systems Development</i>
---	---

B. Program Change Summary (\$ in Millions)	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total
Previous President's Budget	21.068	21.489	64.030	0.000	64.030
Current President's Budget	21.068	21.489	64.030	0.000	64.030
Total Adjustments	0.000	0.000	0.000	0.000	0.000
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-	-			

Congressional Add Details (\$ in Millions, and Includes General Reductions)

Project: 500A: *CSI - Congressional Special Interests*

 Congressional Add: *CSI - Congressional Speical Interest*

Congressional Add Subtotals for Project: 500A

Project: 375D: *GDF - Medical Products and Support System Development*

 Congressional Add: *GDF MPSACD Medical Products and Support System Development*

Congressional Add Subtotals for Project: 375D

Congressional Add Totals for all Projects

	FY 2021	FY 2022
	0.000	-
	0.000	-
	0.000	0.000
	0.000	0.000
	0.000	0.000

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency **Date:** April 2022

Appropriation/Budget Activity 0130 / 2					R-1 Program Element (Number/Name) PE 0605145DHA / Medical Products and Support Systems Development				Project (Number/Name) 500A / CSI - Congressional Special Interests			
COST (\$ in Millions)	Prior Years	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total	FY 2024	FY 2025	FY 2026	FY 2027	Cost To Complete	Total Cost
500A: CSI - Congressional Special Interests	18.382	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing

A. Mission Description and Budget Item Justification

In FY 2019, the Defense Health Program funded Congressional Special Interest (CSI) directed research. The strategy for the FY 2018 Congressionally-directed research program is to stimulate innovative research through a competitive, focused, peer-reviewed medical research at intramural and extramural research sites. Because of the CSI annual structure, out-year funding is not programmed.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2021	FY 2022
Congressional Add: CSI - Congressional Special Interest	0.000	-
FY 2021 Accomplishments: No CSI		
Congressional Adds Subtotals	0.000	-

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

N/A

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency **Date:** April 2022

Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0605145DHA / Medical Products and Support Systems Development	Project (Number/Name) 375 / GDF - Medical Products and Support System Development
--	--	---

COST (\$ in Millions)	Prior Years	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total	FY 2024	FY 2025	FY 2026	FY 2027	Cost To Complete	Total Cost
375: GDF - Medical Products and Support System Development	54.539	21.068	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing

Note

Starting in FY2022 Project 375 is being realigned into Projects 375A, 375B, and 375C.

A. Mission Description and Budget Item Justification

Guidance for Development of the Force-Medical Products and Support Systems Development: This funding supports materiel development activities that further system development and demonstration prior to initial full rate production and fielding of commodities.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total
Title: GDF - Medical Products and Support Systems Development (GDF-MPSSD)	21.068	-	-	-	-
Description: GDF-Medical Products and Support Systems Development: This funding supports activities to support system development and demonstration prior to initial full rate production and fielding of medical commodities delivered from 0604110HP (Medical Products Support and Advanced Concept Development). Materiel development may include accelerated transition of US Food and Drug Administration (FDA)-licensed and unregulated products through clinical and field validation studies, advanced prototyping, risk reduction, operational test and evaluation, manufacturing, and product transition efforts for medical information technology applications and medical training systems technologies.					
Accomplishments/Planned Programs Subtotals	21.068	-	-	-	-

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

N/A

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency **Date:** April 2022

Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0605145DHA / Medical Products and Support Systems Development	Project (Number/Name) 375A / GDF - Medical Simulation and Training
--	--	--

COST (\$ in Millions)	Prior Years	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total	FY 2024	FY 2025	FY 2026	FY 2027	Cost To Complete	Total Cost
375A: GDF - Medical Simulation and Training	0.000	0.000	2.000	2.000	0.000	2.000	2.000	2.000	2.000	2.040	Continuing	Continuing

Note
Starting in FY 2022, Project 375A was realigned from Project 375. This Project is not a new start.

A. Mission Description and Budget Item Justification

Guidance for Development of the Force-Medical Simulation and Training: This funding supports material development activities that enhance system development and demonstration prior to initial full rate production and fielding of capabilities.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total
Title: GDF - Medical Simulation and Training	0.000	2.000	2.000	0.000	2.000
Description: GDF-Medical Products and Support Systems Development: This funding enhances activities to support system development and demonstration prior to initial full rate production and fielding of medical simulation delivered from 0604110HP (Medical Simulation and Training, Advanced Concept Development). Materiel development may include accelerated transition of Medical Simulation products through clinical and field validation studies, advanced prototyping, risk reduction, operational test and evaluation, manufacturing, and product transition efforts for medical information technology applications and medical training systems technologies.					
FY 2022 Plans: Programs will focus on development and application of medical simulation and training capabilities for hospital care and operations. Medical Simulation Training Systems will begin to develop standardized training capabilities for point of injury, trauma simulation, hospital training, along with a common platform architecture that improves medical care across the DoD.					
FY 2023 Base Plans: FY2023 plans continue efforts as outlined in FY 2022 and support the development and demonstration of medical simulation capabilities.					
FY 2023 OCO Plans: N/A					
FY 2022 to FY 2023 Increase/Decrease Statement:					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency		Date: April 2022
Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0605145DHA / <i>Medical Products and Support Systems Development</i>	Project (Number/Name) 375A / <i>GDF - Medical Simulation and Training</i>

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total
None					
Accomplishments/Planned Programs Subtotals	0.000	2.000	2.000	0.000	2.000

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

This program will test and evaluate medical simulation products and platforms developed in order to review data for operational and clinical use prior to production and fielding.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency **Date:** April 2022

Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0605145DHA / Medical Products and Support Systems Development	Project (Number/Name) 375B / GDF - Medical Readiness
--	--	--

COST (\$ in Millions)	Prior Years	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total	FY 2024	FY 2025	FY 2026	FY 2027	Cost To Complete	Total Cost
375B: GDF - Medical Readiness	0.000	0.000	8.536	5.725	0.000	5.725	5.674	5.967	7.490	7.641	Continuing	Continuing

Note
Starting in FY 2022, Project 375B was realigned from Project 375. This Project is not a new start.

A. Mission Description and Budget Item Justification

Guidance for Development of the Force-Medical Readiness: This funding supports material development activities that enhance system development and demonstration prior to initial full rate production and fielding of capabilities.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total
<p>Title: GDF - Medical Readiness</p> <p>Description: GDF-Medical Readiness: This funding enhances activities to support system development and demonstration prior to initial full rate production and fielding of medical readiness capability delivered from 0604110HP (Medical Readiness, Advanced Concept Development). Materiel development may include accelerated transition of Medical Readiness products through clinical and field validation studies, advanced prototyping, risk reduction, operational test and evaluation, manufacturing, and product transition efforts for medical information technology applications and medical readiness systems technologies.</p> <p>FY 2022 Plans: Programs will focus on prevention of illness and injury along with optimization of human performance. Significant FY22 Programs: the Health Readiness and Performance System (HRAPS) plans to begin User Testing and Operational Assessment of its platform. Also, efforts will continue for Heat Optimization Decision Aids (HODA) program and Healthy Eating, Activity, & Lifestyle Training Headquarters (HEALTH) Decision Aid program.</p> <p>FY 2023 Base Plans: FY2023 plans continue efforts as outlined in FY 2022 and support the development and demonstration of medical readiness capabilities.</p> <p>FY 2023 OCO Plans: N/A</p> <p>FY 2022 to FY 2023 Increase/Decrease Statement:</p>	0.000	8.536	5.725	0.000	5.725

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency		Date: April 2022
Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0605145DHA / <i>Medical Products and Support Systems Development</i>	Project (Number/Name) 375B / <i>GDF - Medical Readiness</i>

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total
Increase due to inflation program growth.					
Accomplishments/Planned Programs Subtotals	0.000	8.536	5.725	0.000	5.725

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

This program will test and evaluate medical products in government-managed clinical trials in order to gather data to meet military and regulatory (e.g., FDA, Environmental Protection Agency) requirements for production and fielding.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency **Date:** April 2022

Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0605145DHA / Medical Products and Support Systems Development	Project (Number/Name) 375C / GDF - Medical Combat Support
--	--	---

COST (\$ in Millions)	Prior Years	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total	FY 2024	FY 2025	FY 2026	FY 2027	Cost To Complete	Total Cost
375C: GDF - Medical Combat Support	0.000	0.000	10.953	14.194	0.000	14.194	14.683	14.838	13.770	14.045	Continuing	Continuing

Note
Starting in FY 2022, Project 375C was realigned from Project 375. This Project is not a new start.

A. Mission Description and Budget Item Justification

Guidance for Development of the Force-Medical Combat Support: This funding supports material development activities that enhance system development and demonstration prior to initial full rate production and fielding of capabilities.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total
Title: GDF - Medical Combat Support	0.000	10.953	14.194	0.000	14.194
Description: GDF-Medical Combat Support: This funding enhances activities to support system development and demonstration prior to initial full rate production and fielding of medical readiness capability delivered from 0604110HP (Medical Combat Support, Advanced Concept Development). Materiel development may include accelerated transition of Medical Combat Support products through clinical and field validation studies, advanced prototyping, risk reduction, operational test and evaluation, manufacturing, and product transition efforts for medical information technology applications and medical combat support systems technologies.					
FY 2022 Plans: Programs will focus on the continued operational support of Expeditionary Medical Refrigeration Unit (EMRU) program plans to achieve IOC and begin the process for fielding. Also, efforts will continue for Battlefield Pain Management – Ketamine and Joint Medical Exchange & Documentation of Information for Combat Casualty Care (J-MEDIC3).					
FY 2023 Base Plans: FY2023 plans continue efforts as outlined in FY 2022 and support the development and demonstration of medical combat support capabilities.					
FY 2023 OCO Plans: N/A					
FY 2022 to FY 2023 Increase/Decrease Statement:					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency		Date: April 2022
Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0605145DHA / <i>Medical Products and Support Systems Development</i>	Project (Number/Name) 375C / <i>GDF - Medical Combat Support</i>

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total
Increase due to inflation program growth.					
Accomplishments/Planned Programs Subtotals	0.000	10.953	14.194	0.000	14.194

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

This program will test and evaluate medical products in government-managed clinical trials in order to gather data to meet military and regulatory (e.g., FDA, Environmental Protection Agency) requirements for production and fielding.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency										Date: April 2022		
Appropriation/Budget Activity 0130 / 2					R-1 Program Element (Number/Name) PE 0605145DHA / Medical Products and Support Systems Development				Project (Number/Name) 375D / GDF - Medical Products and Support System Development			
COST (\$ in Millions)	Prior Years	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total	FY 2024	FY 2025	FY 2026	FY 2027	Cost To Complete	Total Cost
375D: GDF - Medical Products and Support System Development	0.000	0.000	0.000	42.111	0.000	42.111	36.205	35.090	38.933	39.322	Continuing	Continuing

A. Mission Description and Budget Item Justification

Funding and mission realignment of US Army Medical Research and Development Command transfer to the Defense Health Agency in order to meet Congressional intent as outlined in NDAA 2019 (Section 711) and NDAA 2020 (Section 737) in support of Medical Products and Support System Development.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total
Title: GDF MPSACD Medical Products and Support System Development	0.000	0.000	42.111	0.000	42.111
Description: Programmatic transfer in accordance with the 711/737 US Army Medical Research and Development Command transfer to Defense Health Agency in support of Medical Products and Support System Development from Army PEs 0604807A.					
FY 2022 Plans: N/A					
FY 2023 Base Plans: Programs will focus on System Development and Demonstration in support of Medical Products and Support Systems.					
FY 2023 OCO Plans: N/A					
FY 2022 to FY 2023 Increase/Decrease Statement: Funding increase for this Project was due to transfer/realignment from Army.					
Accomplishments/Planned Programs Subtotals	0.000	0.000	42.111	0.000	42.111
	FY 2021	FY 2022			
Congressional Add: GDF MPSACD Medical Products and Support System Development	0.000	0.000			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency		Date: April 2022	
Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0605145DHA / <i>Medical Products and Support Systems Development</i>	Project (Number/Name) 375D / <i>GDF - Medical Products and Support System Development</i>	
		FY 2021	FY 2022
<i>FY 2021 Accomplishments:</i> N/A			
<i>FY 2022 Plans:</i> N/A			
Congressional Adds Subtotals		0.000	0.000

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

N/A